These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 20299059)

  • 21. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
    Isbarn H; Karakiewicz PI; Shariat SF; Capitanio U; Palapattu GS; Sagalowsky AI; Lotan Y; Schoenberg MP; Amiel GE; Lerner SP; Sonpavde G
    J Urol; 2009 Aug; 182(2):459-65; discussion 465. PubMed ID: 19524971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection.
    Nielsen ME; Bastian PJ; Palapattu GS; Trock BJ; Schoenberg MP; Chan T; Rogers CG
    Urology; 2007 Dec; 70(6):1091-5. PubMed ID: 18158024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.
    Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE
    Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy.
    Shariat SF; Palapattu GS; Amiel GE; Karakiewicz PI; Rogers CG; Vazina A; Schoenberg MP; Lerner SP; Sagalowsky AI; Lotan Y
    Urology; 2006 Sep; 68(3):538-42. PubMed ID: 16979748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
    Gupta A; Lotan Y; Bastian PJ; Palapattu GS; Karakiewicz PI; Raj GV; Schoenberg MP; Lerner SP; Sagalowsky AI; Shariat SF;
    Urology; 2008 Feb; 71(2):302-7. PubMed ID: 18308108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy.
    Bruins HM; Huang GJ; Cai J; Skinner DG; Stein JP; Penson DF
    J Urol; 2009 Nov; 182(5):2182-7. PubMed ID: 19758623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
    Zhang M; Tao R; Zhang C; Shen Z
    Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival.
    Bastian PJ; Hutterer GC; Shariat SF; Rogers CG; Palapattu GS; Lotan Y; Vazina A; Amiel GE; Gupta A; Sagalowsky AI; Lerner SP; Schoenberg MP; Karakiewicz PI;
    BJU Int; 2008 Feb; 101(4):450-4. PubMed ID: 17850359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients.
    Stein JP; Clark P; Miranda G; Cai J; Groshen S; Skinner DG
    J Urol; 2005 Apr; 173(4):1163-8. PubMed ID: 15758728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial.
    Bolenz C; Herrmann E; Bastian PJ; Michel MS; Wülfing C; Tiemann A; Buchner A; Stief CG; Fritsche HM; Burger M; Wieland WF; Höfner T; Haferkamp A; Hohenfellner M; Müller SC; Ströbel P; Trojan L
    BJU Int; 2010 Aug; 106(4):493-9. PubMed ID: 20067452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
    Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
    J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer specific outcomes in patients with pT0 disease following radical cystectomy.
    Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Lotan Y; Vazina A; Gupta A; Sagalowsky AI; Lerner SP; Schoenberg MP;
    J Urol; 2006 May; 175(5):1645-9; discussion 1649. PubMed ID: 16600721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis.
    Canter D; Guzzo T; Resnick M; Magerfleisch L; Sonnad S; Bergey M; Tomazewski J; Vaughn D; Van Arsdalen K; Malkowicz B
    BJU Int; 2008 Sep; 102(8):952-7. PubMed ID: 18485042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
    Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
    J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
    Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy.
    Harada K; Sakai I; Hara I; Eto H; Miyake H
    Int J Urol; 2005 Mar; 12(3):250-5. PubMed ID: 15828951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.